Cyclo Therapeutics Statistics
Share Statistics
Cyclo Therapeutics has 135.43M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 135.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.29 and the forward PE ratio is null.
| PE Ratio | -1.29 |
| Forward PE | null |
| PS Ratio | 24.12 |
| Forward PS | null |
| PB Ratio | 5.46 |
| P/FCF Ratio | -1.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Cyclo Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.45 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 17.84 |
| Cash Flow / Debt | -15.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -4.22% and return on capital (ROIC) is -346.28%.
| Return on Equity (ROE) | -4.22% |
| Return on Assets (ROA) | -1.51% |
| Return on Capital (ROIC) | -346.28% |
| Revenue Per Employee | 134.55K |
| Profits Per Employee | -2.51M |
| Employee Count | 8 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.38, so Cyclo Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.38 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Cyclo Therapeutics had revenue of $1.08M and earned -$20.06M in profits. Earnings per share was $-1.23.
| Revenue | 1.08M |
| Gross Profit | 977.95K |
| Operating Income | -20.05M |
| Net Income | -20.06M |
| EBITDA | -20.03M |
| EBIT | -20.05M |
| Earnings Per Share (EPS) | -1.23 |
Balance Sheet
The company has $9.25M in cash and $1.03M in debt, giving a net cash position of $8.21M.
| Cash & Cash Equivalents | 9.25M |
| Total Debt | 1.03M |
| Net Cash | 8.21M |
| Retained Earnings | -83.86M |
| Total Assets | 5.25M |
| Working Capital | -15.46M |
Cash Flow
In the last 12 months, operating cash flow was -$16.19M and capital expenditures -$2.42K, giving a free cash flow of -$16.19M.
| Operating Cash Flow | -16.19M |
| Capital Expenditures | -2.42K |
| Free Cash Flow | -16.19M |
| FCF Per Share | -0.99 |
Margins
Gross margin is 90.85%, with operating and profit margins of -1.86K% and -1.86K%.
| Gross Margin | 90.85% |
| Operating Margin | -1.86K% |
| Pretax Margin | -1.86K% |
| Profit Margin | -1.86K% |
| EBITDA Margin | -1.86K% |
| EBIT Margin | -1.86K% |
| FCF Margin | -1.50K% |
Dividends & Yields
CYTHW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CYTHW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -45.75 |
| Piotroski F-Score | 2 |